Neurocrine Biosciences (NBIX): Reiterating Overweight Ahead Of ASRM - Piper Jaffray
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Neurocrine Bio. (NASDAQ: NBIX) ahead of of Wednesday’s presentations at ASRM.
The analyst reviewed the efficacy and safety results on elagolix and other GnRH antagonists in development. Based on comparing the early Phase II data from potential competitors to the available Phase II & III elagolix data, the analyst sees only incremental, if any, benefits from these 2 nd-generation agents. Elagolix seems to have a clear advantage in terms of patients evaluated & efficacy/safety results to date, dosing flexibility (1-2x times daily and with or without add-back therapy), first-to-market status, and experienced commercial partner AbbVie.
No change to the price target of $96.
Shares of Neurocrine Bio. closed at $42.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Cuts Price Target on Neurocrine Biosciences (NBIX) Following Study
- Alcobra (ADHD) PT Cut to $1.50 at Piper Jaffray as MDX P3 Misses
- Jefferies Downgrades Alcobra Ltd. (ADHD) to Hold
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesPiper Jaffray, Charles Duncan
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!